An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP [EXTENSION OF 700009800]

Trial Profile

An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP [EXTENSION OF 700009800]

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2014

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 01 May 2014 Results published in The Journal of Rheumatology.
    • 28 Mar 2008 Status change
    • 22 Mar 2008 Status change from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top